BAM
ADPT icon

Belpointe Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Belpointe Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-153
Closed -$1.35K – 651
2023
Q1 		$1.35K Sell
153
-1,324
-90% -$11.7K ﹤0.01% 3409
2022
Q4 		$11.3K Buy
+1,477
New +$11.5K ﹤0.01% 2552

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Belpointe Asset Management's ADPT Position: Q2 2023 in Review

Belpointe Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2023, closing a stake of 153 shares — an estimated $1.35K sold.

Belpointe Asset Management first reported a position in ADPT in Q4 2022 and held it in 2 quarters. The position peaked at $11.3K in Q4 2022. 210 funds tracked by Wall St. Rank hold ADPT as of Q2 2023.

  • Belpointe Asset Management reported no remaining Adaptive Biotechnologies position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 153 Adaptive Biotechnologies shares in Q2 2023, an estimated $1.35K.
  • Belpointe Asset Management first reported a position in Adaptive Biotechnologies in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Adaptive Biotechnologies position peaked at $11.3K in Q4 2022.
  • 210 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.